Novo Nordisk, a global healthcare company, has launched Tresiba (insulin degludec) in Denmark for people with type 1 and type 2 diabetes.
Tresiba is indicated for the treatment of diabetes mellitus in adults as monotherapy or in combination with oral antidiabetic agents or rapid-acting insulin delivery device.
Tresiba is a new long-acting insulin, which is dosed once daily. Studies have shown that Tresiba lowers blood glucose levels and simultaneously reduce the risk of hypoglycemia, especially at night, compared with insulin glargine, Cases of nocturnal hypoglycemia (low blood sugar in diabetics), is a particular problem for people with diabetes because cases are often unpredictable and difficult to detect and respond PAA. Fear of hypoglycaemia can lead to insulin not always taken exactly as prescribed, increasing the risk of senkomplikationer.
Mads Krogsgaard, director of Research at Novo Nordisk, said, "By the insulin treatment, we have known so far is maintaining good blood sugar control is a challenge for both caregivers and people with diabetes, partly because of concerns about the diabetic must have hypoglycemia, especially at night. With Tresiba will be able to reduce incidence of nocturnal hypoglycaemia, and thus more patients to achieve better blood sugar control.”
Tresiba have a very long duration of action greater than 42 hours. This makes it possible to vary the time of injection from day to day as required, without affecting the efficacy or increase the risk of hypoglycaemia.
Tresiba is supplied in a disposable pen Flex Touch, which alone is equipped with an injection button with very little resistance to pressure and allows for doses up to 160 devices in a single injection.
Tresiba provides lower risk of nocturnal hypoglycaemia compared to insulin glargine: 36 per cent of type 2 diabetics who had not previously been treated with insulin (0.25 [insulin degludec] to 0.39 [insulin glargine] episodes per. Per patient. Years, p = 0.04). 25 per cent of type 1 (4.41 [insulin degludec] to 5.86 [insulin glargine] episodes per. Per patient. Years, p = 0.021).
Tresiba was granted marketing authorization by the European Medicines Agencies (EMA), January 22, 2013 and is also approved in Mexico and Japan. Tresiba is available in a prefilled (Tresiba Flex Touch) and ampoules (Tresiba Penfill) for use with Novo Nordisk insulin delivery systems.